Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with alzheimer's parents

Neurobiology of Aging

Volumn 34, Issue 1, 2013, Pages 22-34

  Mosconi, Lisa ^a   Rinne, Juha O ^b   Tsui, Wai H ^a,c   Murray, John ^a   Li, Yi ^a   Glodzik, Lidia ^a   McHugh, Pauline ^a   Williams, Schantel ^a   Cummings, Megan ^a   Pirraglia, Elizabeth ^a   Goldsmith, Stanley J ^d   Vallabhajosula, Shankar ^d   Scheinin, Noora ^b   Viljanen, Tapio ^b   Någren, Kjell ^b,e   de Leon, Mony J ^a,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TURKU   (Finland)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Alzheimer's disease; Amyloid; Early detection; Family history; Glucose metabolism; PET imaging

Indexed keywords

AMYLOID BETA PROTEIN; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B;

ACCURACY; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN MAPPING; BRAIN METABOLISM; BRAIN REGION; DISEASE PREDISPOSITION; FAMILY HISTORY; FEMALE; GLUCOSE METABOLISM; HUMAN; HUMAN EXPERIMENT; LEFT HEMISPHERE; MALE; NEUROIMAGING; NORMAL HUMAN; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROTEIN METABOLISM; RIGHT HEMISPHERE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID; ANILINE COMPOUNDS; BRAIN; BRAIN MAPPING; COGNITION DISORDERS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; SENSITIVITY AND SPECIFICITY; THIAZOLES;

EID: 84868159914     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.03.002     Document Type: Article

References (65)

1. Aizenstein H.J., Nebes R.D., Saxton J.A., Price J.C., Mathis C.A., Tsopelas N.D., Ziolko S.K., James J.A., Snitz B.E., Houck P.R., Bi W., Cohen A.D., Lopresti B.J., DeKosky S.T., Halligan E.M., Klunk W.E. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol 2008, 65:1509-1517.
2. Andrawis, J.P., Hwang, K.S., Green, A.E., Kotlerman, J., Elashoff, D., Morra, J.H., Cummings, J.L., Toga, A.W., Thompson, P.M., Apostolova, L.G., in press. Effects of ApoE4 and maternal history of dementia on hippocampal atrophy. Neurobiol. Aging. doi:S0197-4580(10)00342-8 [pii]. doi:10.1016/j.neurobiolaging.%202010.07.020.
3. Arnold S.E., Hyman B.T., Flory J., Damasio A.R., Van Hoesen G.W. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb. Cortex 1991, 1:103-116.
4. Bendlin B.B., Ries M.L., Canu E., Sodhi A., Lazar M., Alexander A.L., Carlsson C.M., Sager M.A., Asthana S., Johnson S.C. White matter is altered with parental family history of Alzheimer's disease. Alzheimers Dement 2010, 6:394-403.
5. Bennett D.A., Schneider J.A., Arvanitakis Z., Kelly J.F., Aggarwal N.T., Shah R.C., Wilson R.S. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006, 66:1837-1844.
6. Bertram L., Lill C.M., Tanzi R.E. The genetics of Alzheimer disease: back to the future. Neuron 2010, 68:270-281.
7. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991, 8:239-259.
8. Braak H., Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 1997, 18:351-357.
9. Buckner R.L., Sepulcre J., Talukdar T., Krienen F.M., Liu H., Hedden T., Andrews-Hanna J.R., Sperling R.A., Johnson K.A. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J. Neurosci 2009, 29:1860-1873.
10. Casanova R., Srikanth R., Baer A., Laurienti P.J., Burdette J.H., Hayasaka S., Flowers L., Wood F., Maldjian J.A. Biological parametric mapping: a statistical toolbox for multimodality brain image analysis. Neuroimage 2007, 34:137-143.
11. Cohen A.D., Price J.C., Weissfeld L.A., James J., Rosario B.L., Bi W., Nebes R.D., Saxton J.A., Snitz B.E., Aizenstein H.A., Wolk D.A., Dekosky S.T., Mathis C.A., Klunk W.E. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J. Neurosci 2009, 29:14770-14778.
12. Debette S., Wolf P.A., Beiser A., Au R., Himali J.J., Pikula A., Auerbach S., Decarli C., Seshadri S. Association of parental dementia with cognitive and brain MRI measures in middle-aged adults. Neurology 2009, 73:2071-2078.
13. Delacourte A., David J.P., Sergeant N., Buée L., Wattez A., Vermersch P., Ghozali F., Fallet-Bianco C., Pasquier F., Lebert F., Petit H., Di Menza C. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 1999, 52:1158-1165.
14. Drzezga A., Becker J.A., Van Dijk K.R., Sreenivasan A., Talukdar T., Sullivan C., Schultz A.P., Sepulcre J., Putcha D., Greve D., Johnson K.A., Sperling R.A. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain 2011, 134:1635-1646.
15. Duara R., Barker W.W., Lopez-Alberola R., Loewenstein D.A., Grau L.B., Gilchrist D., Sevush S., St George-Hyslop S. Alzheimer's disease: interaction of apolipoprotein E genotype, family history of dementia, gender, education, ethnicity, and age of onset. Neurology 1996, 46:1575-1579.
16. Edison P., Archer H.A., Hinz R., Hammers A., Pavese N., Tai Y.F., Hotton G., Cutler D., Fox N., Kennedy A., Rossor M., Brooks D.J. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007, 68:501-508.
17. Edland S.D., Silverman J.M., Peskind E.R., Tsuang D., Wijsman E., Morris J.C. Increased risk of dementia in mothers of Alzheimer's disease cases: evidence for maternal inheritance. Neurology 1996, 47:254-256.
18. Engler H., Forsberg A., Almkvist O., Blomquist G., Larsson E., Savitcheva I., Wall A., Ringheim A., Långström B., Nordberg A. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006, 129:2856-2866.
19. Farrer L.A., O'Sullivan D.M., Cupples L.A., Growdon J.H., Myers R.H. Assessment of genetic risk for Alzheimer's disease among first-degree relatives. Ann. Neurol 1989, 25:485-493.
20. Forsberg A., Engler H., Almkvist O., Blomquist G., Hagman G., Wall A., Ringheim A., Långström B., Nordberg A. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 2008, 29:1456-1465.
21. Frisoni G.B., Lorenzi M., Caroli A., Kemppainen N., Någren K., Rinne J.O. In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology 2009, 72:1504-1511.
22. Friston K.J., Frith C.D., Liddle P.F., Frackowiak R.S. Comparing functional (PET) images: the assessment of significant change. J. Cereb. Blood Flow Metab 1991, 11:690-699.
23. Furst A.J., Rabinovici G.D., Rostomian A.H., Steed T., Alkalay A., Racine C., Miller B.L., Jagust W.J. Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol. Aging 2012, 33:215-225.
24. Gómez-Tortosa E., Barquero M.S., Barón M., Sainz M.J., Manzano S., Payno M., Ros R., Almaraz C., Gómez-Garré P., Jiménez-Escrig A. Variability of age at onset in siblings with familial Alzheimer disease. Arch. Neurol 2007, 64:1743-1748.
25. Good C.D., Johnsrude I.S., Ashburner J., Henson R.N., Friston K.J., Frackowiak R.S.J. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 2001, 14:21-36.
26. Grimmer T., Tholen S., Yousefi B.H., Alexopoulos P., Förschler A., Förstl H., Henriksen G., Klunk W.E., Mathis C.A., Perneczky R., Sorg C., Kurz A., Drzezga A. Progression of cerebral amyloid load is associated with the apolipoprotein E epsilon4 genotype in Alzheimer's disease. Biol. Psychiatry 2010, 68:879-884.
27. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol 2007, 8:101-112.
28. Herholz K. PET studies in dementia. Ann. Nucl. Med 2003, 17:79-89.
29. Honea R.A., Swerdlow R.H., Vidoni E.D., Burns J.M. Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease. Neurology 2011, 76:822-829.
30. Honea R.A., Swerdlow R.H., Vidoni E.D., Goodwin J., Burns J.M. Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease. Neurology 2010, 74:113-120.
31. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9:119-128.
32. Jack C.R., Lowe V.J., Weigand S.D., Wiste H.J., Senjem M.L., Knopman D.S., Shiung M.M., Gunter J.L., Boeve B.F., Kemp B.J., Weiner M., Petersen R.C. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132:1355-1365.
33. Jack C.R., Lowe V.J., Senjem M.L., Weigand S.D., Kemp B.J., Shiung M.M., Knopman D.S., Boeve B.F., Klunk W.E., Mathis C.A., Petersen R.C. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008, 131:665-680.
34. Jagust W.J., Landau S.M., Shaw L.M., Trojanowski J.Q., Koeppe R.A., Reiman E.M., Foster N.L., Petersen R.C., Weiner M.W., Price J.C., Mathis C.A. Relationships between biomarkers in aging and dementia. Neurology 2009, 73:1193-1199.
35. Kawas C., Segal J., Stewart W.F., Corrada M., Thal L.J. A validation study of the Dementia Questionnaire. Arch. Neurol 1994, 51:901-906.
36. Kemppainen N.M., Aalto S., Karrasch M., Någren K., Savisto N., Oikonen V., Viitanen M., Parkkola R., Rinne J.O. Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann. Neurol 2008, 63:112-118.
37. Kemppainen N.M., Aalto S., Wilson I.A., Någren K., Helin S., Brück A., Oikonen V., Kailajärvi M., Scheinin M., Viitanen M., Parkkola R., Rinne J.O. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006, 67:1575-1580.
38. Kemppainen N.M., Aalto S., Wilson I.A., Någren K., Helin S., Brück A., Oikonen V., Kailajärvi M., Scheinin M., Viitanen M., Parkkola R., Rinne J.O. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007, 68:1603-1606.
39. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergström M., Savitcheva I., Huang G.F., Estrada S., Ausén B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Långström B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol 2004, 55:306-319.
40. Klunk W.E., Mathis C.A., Price J.C., Lopresti B.J., DeKosky S.T. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006, 129:2805-2807.
41. Li Y., Rinne J.O., Mosconi L., Pirraglia E., Rusinek H., DeSanti S., Kemppainen N., Någren K., Kim B.C., Tsui W., de Leon M.J. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:2169-2181.
42. Mark R.J., Pang Z., Geddes J.W., Uchida K., Mattson M.P. Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J. Neurosci 1997, 17:1046-1054.
43. Meguro K., Blaizot X., Kondoh Y., Le Mestric C., Baron J.C., Chavoix C. Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease. Brain 1999, 122:1519-1531.
44. Mintun M.A., Larossa G.N., Sheline Y.I., Dence C.S., Lee S.Y., Mach R.H., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006, 67:446-452.
45. Mormino E.C., Kluth J.T., Madison C.M., Rabinovici G.D., Baker S.L., Miller B.L., Koeppe R.A., Mathis C.A., Weiner M.W., Jagust W.J. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009, 132:1310-1323.
46. Morris J.C., Roe C.M., Xiong C., Fagan A.M., Goate A.M., Holtzman D.M., Mintun M.A. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann. Neurol 2010, 67:122-131.
47. Morrison J.H., Hof P.R. Life and death of neurons in the aging brain. Science 1997, 278:412-419.
48. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2005, 32:486-510.
49. Mosconi L., Berti V., Glodzik L., Pupi A., De Santi S., de Leon M.J. Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J. Alzheimers Dis 2010, 20:843-854.
50. Mosconi L., Berti V., Swerdlow R.H., Pupi A., Duara R., de Leon M. Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes. Hum. Genomics 2010, 4:170-193.
51. Mosconi L., Brys M., Switalski R., Mistur R., Glodzik L., Pirraglia E., Tsui W., De Santi S., de Leon M.J. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19067-19072.
52. Mosconi L., Glodzik L., Mistur R., McHugh P., Rich K.E., Javier E., Williams S., Pirraglia E., De Santi S., Mehta P.D., Zinkowski R., Blennow K., Pratico D., de Leon M.J. Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer's. Biol. Psychiatry 2010, 68:913-921.
53. Mosconi L., Mistur R., Switalski R., Brys M., Glodzik L., Rich K., Pirraglia E., Tsui W., De Santi S., de Leon M.J. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology 2009, 72:513-520.
54. Mosconi L., Rinne J.O., Tsui W.H., Berti V., Li Y., Wang H., Murray J., Scheinin N., Nagren K., Williams S., Glodzik L., De Santi S., Vallabhajosula S., de Leon M.J. Increased fibrillar amyloid-beta burden in normal individuals with a family history of late-onset Alzheimer's. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:5949-5954.
55. Mosconi L., Tsui W.H., De Santi S., Li J., Rusinek H., Convit A., Li Y., Boppana M., de Leon M.J. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 2005, 64:1860-1867.
56. Pike K.E., Savage G., Villemagne V.L., Ng S., Moss S.A., Maruff P., Mathis C.A., Klunk W.E., Masters C.L., Rowe C.C. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007, 130:2837-2844.
57. Price J.C., Klunk W.E., Lopresti B.J., Lu X., Hoge J.A., Ziolko S.K., Holt D.P., Meltzer C.C., DeKosky S.T., Mathis C.A. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J. Cereb. Blood Flow Metab 2005, 25:1528-1547.
58. Price J.L., Morris J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol 1999, 45:358-368.
59. Reiman E.M., Chen K., Liu X., Bandy D., Yu M., Lee W., Ayutyanont N., Keppler J., Reeder S.A., Langbaum J.B., Alexander G.E., Klunk W.E., Mathis C.A., Price J.C., Aizenstein H.J., DeKosky S.T., Caselli R.J. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:6820-6825.
60. Rocher A.B., Chapon F., Blaizot X., Baron J.-C., Chavoix C. Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons. Neuroimage 2004, 20:1894-1898.
61. Sokoloff L., Reivich M., Kennedy C., Des Rosiers M.H., Patlak C.S., Pettigrew K.D., Sakurada O., Shinohara M. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem 1977, 28:897-916.
62. Storandt M., Mintun M.A., Head D., Morris J.C. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch. Neurol 2009, 66:1476-1481.
63. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol 1991, 30:572-580.
64. Thal D.R., Rüb U., Orantes M., Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58:1791-1800.
65. Valla J., Yaari R., Wolf A.B., Kusne Y., Beach T.G., Roher A.E., Corneveaux J.J., Huentelman M.J., Caselli R.J., Reiman E.M. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE epsilon4 allele, the major late-onset Alzheimer's susceptibility gene. J. Alzheimers Dis 2010, 22:307-313.